Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $521M | $17M | $-23M | $55M | -7.4% | 54.7% | -73.4% |
| 2024 | $337M | $-49M | $-88M | $-11M | -39.0% | 80.8% | -46.2% |
| 2023 | $186M | $-136M | $-163M | $-91M | -65.7% | 141.8% | 20.5% |
| 2022 | $77M | $-123M | $-136M | $-120M | -95.5% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 77.06 | 186.37 | 336.89 | 521.31 |
| Operating Revenue | - | 77.06 | 186.37 | 336.89 | 521.31 |
| Cost Of Revenue | - | 12.37 | 47.04 | 81.64 | 100.24 |
| Gross Profit | - | 64.69 | 139.34 | 255.24 | 421.07 |
| Operating Expense | - | 195.91 | 248.49 | 342.85 | 443.21 |
| Research And Development | - | 106.84 | 102.61 | 140.63 | 186.18 |
| Selling General And Administration | - | 89.07 | 145.88 | 202.22 | 257.03 |
| Total Expenses | - | 208.28 | 295.53 | 424.49 | 543.45 |
| Operating Income | - | -131.22 | -109.15 | -87.61 | -22.14 |
| Total Operating Income As Reported | - | -131.22 | -109.15 | -87.61 | -22.14 |
| EBITDA | - | -122.85 | -136.49 | -48.97 | 17.21 |
| Normalized EBITDA | - | -123.76 | -87.41 | -48.97 | 17.21 |
| EBIT | - | -126.09 | -147.32 | -72.60 | -7.04 |
| Interest Income | - | 3.86 | 13.74 | 13.79 | 12.73 |
| Interest Expense | - | 15.98 | 15.10 | 14.31 | 14.39 |
| Net Interest Income | - | -12.12 | -1.37 | -0.52 | -1.66 |
| Other Non Operating Income Expenses | - | 0.36 | -2.82 | 1.21 | 2.37 |
| Other Income Expense | - | 1.27 | -51.90 | 1.21 | 2.37 |
| Interest Income Non Operating | - | 3.86 | 13.74 | 13.79 | 12.73 |
| Interest Expense Non Operating | - | 15.98 | 15.10 | 14.31 | 14.39 |
| Net Non Operating Interest Income Expense | - | -12.12 | -1.37 | -0.52 | -1.66 |
| Pretax Income | - | -142.07 | -162.42 | -86.91 | -21.43 |
| Tax Provision | - | -6.41 | 0.99 | 1.03 | 1.94 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0.04 | -10.31 | 0 | 0 |
| Net Income Continuous Operations | - | -135.66 | -163.42 | -87.94 | -23.36 |
| Net Income From Continuing And Discontinued Operation | - | -135.66 | -163.42 | -87.94 | -23.36 |
| Net Income From Continuing Operation Net Minority Interest | - | -135.66 | -163.42 | -87.94 | -23.36 |
| Net Income | - | -135.66 | -163.42 | -87.94 | -23.36 |
| Net Income Common Stockholders | - | -135.66 | -163.42 | -87.94 | -23.36 |
| Net Income Including Noncontrolling Interests | - | -135.66 | -163.42 | -87.94 | -23.36 |
| Normalized Income | - | -136.53 | -124.64 | -87.94 | -23.36 |
| Diluted NI Availto Com Stockholders | - | -136.58 | -163.42 | -87.94 | -23.36 |
| Basic Average Shares | - | 33.84 | 40.89 | 47.52 | 50.20 |
| Diluted Average Shares | - | 33.98 | 40.89 | 47.52 | 50.20 |
| Reconciled Depreciation | - | 3.24 | 10.83 | 23.63 | 24.24 |
| Reconciled Cost Of Revenue | - | 12.37 | 47.04 | 81.64 | 100.24 |
| Total Unusual Items | - | 0.91 | -49.08 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | - | 0.91 | -49.08 | 0 | 0 |
| Special Income Charges | - | 0 | -49.08 | 0 | 0 |
| Other Special Charges | - | - | 49.08 | - | - |
| Gain On Sale Of Security | -0.73 | 0.91 | - | - | - |
| Average Dilution Earnings | 0 | -0.91 | 0 | 0 | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc.this co. | MIRM | $5.6B | -241.41 | 17.92 | -7.4% | 329.12 |
| Kymera Therapeutics, Inc. | KYMR | $6.1B | - | 3.89 | -19.7% | - |
| Terns Pharmaceuticals, Inc. | TERN | $6.1B | -63.58 | 6.08 | -9.6% | -51.02 |
| Rhythm Pharmaceuticals, Inc. | RYTM | $6.0B | - | 22.25 | -74.8% | - |
| PACS Group, Inc. | PACS |
| - |
| - |
| - |
| - |
| - |
| - |
| $5.9B |
| 30.96 |
| 6.26 |
| 20.2% |
| 24.98 |
| Cogent Biosciences, Inc. | COGT | $5.6B | -17.03 | 10.24 | -60.1% | -17.21 |
| Liquidia Corporation | LQDA | $5.6B | -80.69 | 124.29 | -154.0% | -128.84 |
| CRISPR Therapeutics AG | CRSP | $5.5B | - | 2.86 | -30.3% | - |
| Scholar Rock Holding Corporation | SRRK | $5.4B | - | 22.13 | -154.0% | - |
| Peer Median | - | -40.31 | 8.25 | -45.2% | -34.12 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Jan has averaged the highest return (+15.7%); Oct the lowest (-5.7%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +30.7%Positive MonthJan 2026: +30.67% | -10.6%Negative MonthFeb 2026: -10.59% | +0.1%Neutral MonthMar 2026: +0.10% | +5.3%Positive MonthApr 2026: +5.34% | +4.3%Positive MonthMay 2026: +4.31% | +15.3%Positive MonthJun 2026: +15.34% | -9.5%Negative MonthJul 2026: -9.50% | -3.5%*Negative MonthAug 2026: -3.50% | — | — | — | — |
| 2025 | +18.2%Positive MonthJan 2025: +18.21% | -2.7%Negative MonthFeb 2025: -2.68% | -5.3%Negative MonthMar 2025: -5.30% | -3.6%Negative MonthApr 2025: -3.55% | +2.3%Positive MonthMay 2025: +2.32% | +14.5%Positive MonthJun 2025: +14.46% | +1.6%Neutral MonthJul 2025: +1.55% | +42.9%Positive MonthAug 2025: +42.94% | -0.8%Neutral MonthSep 2025: -0.76% | -0.9%Neutral MonthOct 2025: -0.90% | +0.6%Neutral MonthNov 2025: +0.55% | +8.1%Positive MonthDec 2025: +8.13% |
| 2024 | -10.4%Negative MonthJan 2024: -10.37% | +8.5%Positive MonthFeb 2024: +8.50% | -12.5%Negative MonthMar 2024: -12.50% | -0.0%Neutral MonthApr 2024: -0.04% | -4.3%Negative MonthMay 2024: -4.30% | +42.3%Positive MonthJun 2024: +42.28% | +18.6%Positive MonthJul 2024: +18.60% | +6.3%Positive MonthAug 2024: +6.31% | -9.5%Negative MonthSep 2024: -9.53% | -1.4%Neutral MonthOct 2024: -1.38% | +20.2%Positive MonthNov 2024: +20.18% | -10.5%Negative MonthDec 2024: -10.54% |
| 2023 | +20.4%Positive MonthJan 2023: +20.41% | +0.1%Neutral MonthFeb 2023: +0.13% | +2.2%Positive MonthMar 2023: +2.17% | +11.8%Positive MonthApr 2023: +11.78% | -2.3%Negative MonthMay 2023: -2.31% | -1.4%Neutral MonthJun 2023: -1.37% | -0.4%Neutral MonthJul 2023: -0.43% | +2.6%Positive MonthAug 2023: +2.60% | +19.6%Positive MonthSep 2023: +19.56% | -13.2%Negative MonthOct 2023: -13.20% | +16.9%Positive MonthNov 2023: +16.92% | -8.0%Negative MonthDec 2023: -7.95% |
| 2022 | +19.4%Positive MonthJan 2022: +19.44% | +24.4%Positive MonthFeb 2022: +24.41% | -7.1%Negative MonthMar 2022: -7.09% | +8.0%Positive MonthApr 2022: +7.99% | -1.6%Neutral MonthMay 2022: -1.64% | -16.8%Negative MonthJun 2022: -16.80% | +29.0%Positive MonthJul 2022: +28.98% | -0.5%Neutral MonthAug 2022: -0.48% | -15.9%Negative MonthSep 2022: -15.89% | +7.3%Positive MonthOct 2022: +7.33% | -17.3%Negative MonthNov 2022: -17.29% | +4.6%Positive MonthDec 2022: +4.56% |
| 2021 | — | — | — | — | -15.4%Negative MonthMay 2021: -15.35% | +4.5%Positive MonthJun 2021: +4.53% | -16.4%Negative MonthJul 2021: -16.43% | +12.5%Positive MonthAug 2021: +12.46% | +22.6%Positive MonthSep 2021: +22.58% | -20.3%Negative MonthOct 2021: -20.28% | -10.4%Negative MonthNov 2021: -10.39% | +12.1%Positive MonthDec 2021: +12.09% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
